KWKenneth E. White

Kenneth E. White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth E. White has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Emily G. Farrow

    Center for Pediatric Genomic Medicine at Children's Mercy Hospital, Kansas City, and Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA

    9 shared publications
  • Siobhan I. Davis

    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202

    7 shared publications
  • Erica L. Clinkenbeard

    Division of Molecular Genetics and Gene Therapy, Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, Indiana

    6 shared publications
  • Julia M. Hum

    Division of Molecular Genetics and Gene Therapy, Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, Indiana

    6 shared publications
  • Lelia J. Summers

    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA

    5 shared publications
  • Holly J. Garringer

    Pathology and Laboratory Medicine

    4 shared publications

Latest Publications

  • Open Access

    The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model

    by Megan L Noonan, Pu Ni, Rafiou Agoro, Spencer A Sacks, Elizabeth A Swallow, Jonathan A Wheeler, Erica L Clinkenbeard, Maegan L Capitano, Matthew Prideaux, Gerald J Atkins, et al.

    Fibroblast growth factor-23 (FGF23) is a critical factor in chronic kidney disease (CKD), with elevated levels causing alterations in mineral metabolism and increased odds for mortality. Patients with CKD develop anemia as the kidneys progressively lose the ability to produce erythropoietin (EPO). Anemia is a potent driver of FGF23 secretion; therefore, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) currently in clinical trials to elevate endogenous EPO to resolve anemia was tested for effects on iron utilization and FGF23-related parameters in a CKD mouse model. Mice were fed either a casein control diet or an adenine-containing diet to induce CKD. The CKD mice had markedly elevated iFGF23 and blood urea nitrogen (BUN), hyperphosphatemia, and anemia. Cohorts of mice were then treated with a patient-equivalent dose of BAY 85-3934 (BAY; Molidustat), which elevated EPO and completely resolved aberrant complete blood counts (CBCs) in the CKD mice. iFGF23 was elevated in vehicle-treated CKD mice (120-fold), whereas circulating iFGF23 was significantly attenuated (>60%) in the BAY-treated CKD mice. The BAY-treated mice with CKD also had reduced BUN, but there was no effect on renal vitamin D metabolic enzyme expression. Consistent with increased EPO, bone marrow Erfe, Transferrin receptor (Tfrc), and EpoR mRNAs were increased in BAY-treated CKD mice, and in vitro hypoxic marrow cultures increased FGF23 with direct EPO treatment. Liver Bmp-6 and hepcidin expression were downregulated in all BAY-treated groups. Femur trabecular parameters and cortical porosity were not worsened with BAY administration. In vitro, differentiated osteocyte-like cells exposed to an iron chelator to simulate iron depletion/hypoxia increased FGF23; repletion with holo-transferrin completely suppressed FGF23 and normalized Tfrc1. Collectively, these results support that resolving anemia using a HIF-PHI during CKD was associated with lower BUN and reduced FGF23, potentially through direct restoration of iron utilization, thus providing modifiable outcomes beyond improving anemia for this patient population. © 2021 American Society for Bone and Mineral Research (ASBMR).


  • Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy

    by Julia M. Hum, Linda M. O’bryan, Arun K. Tatiparthi, Erica L. Clinkenbeard, Pu Ni, Martin S. Cramer, Manoj Bhaskaran, Robert L. Johnson, Jonathan M. Wilson, Rosamund C. Smith, et al.

    Diabetic nephropathy (DN) is a primary cause of end-stage renal disease and is becoming more prevalent because of the global rise in type 2 diabetes. A model of DN, the db/db uninephrectomized ( db/db-uni) mouse, is characterized by obesity, as well as compromised renal function. This model also manifests defects in mineral metabolism common in DN, including hyperphosphatemia, which leads to severe endocrine disease. The FGF23 coreceptor, α-Klotho, circulates as a soluble, cleaved form (cKL) and may directly influence phosphate handling. Our study sought to test the effects of cKL on mineral metabolism in db/db-uni mice. Mice were placed into either mild or moderate disease groups on the basis of the albumin-to-creatinine ratio (ACR). Body weights of db/db-uni mice were significantly greater across the study compared with lean controls regardless of disease severity. Adeno-associated cKL administration was associated with increased serum Klotho, intact, bioactive FGF23 (iFGF23), and COOH-terminal fragments of FGF23 ( P < 0.05). Blood urea nitrogen was improved after cKL administration, and cKL corrected hyperphosphatemia in the high- and low-ACR db/db-uni groups. Interestingly, 2 wk after cKL delivery, blood glucose levels were significantly reduced in db/db-uni mice with high ACR ( P < 0.05). Interestingly, several genes associated with stabilizing active iFGF23 were also increased in the osteoblastic UMR-106 cell line with cKL treatment. In summary, delivery of cKL to a model of DN normalized blood phosphate levels regardless of disease severity, supporting the concept that targeting cKL-affected pathways could provide future therapeutic avenues in DN. NEW & NOTEWORTHY In this work, systemic and continuous delivery of the “soluble” or “cleaved” form of the FGF23 coreceptor α-Klotho (cKL) via adeno-associated virus to a rodent model of diabetic nephropathy (DN), the db/db uninephrectomized mouse, normalized blood phosphate levels regardless of disease severity. This work supports the concept that targeting cKL-affected pathways could provide future therapeutic avenues for the severe mineral metabolism defects associated with DN.


  • Open Access

    Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD

    by Erica L. Clinkenbeard, Megan L. Noonan, Joseph C. Thomas, Pu Ni, Julia M. Hum, Mohammad Aref, Elizabeth A. Swallow, Sharon M. Moe, Matthew R. Allen, Kenneth E. White

    The phosphaturic hormone FGF23 is elevated in chronic kidney disease (CKD). The risk of premature death is substantially higher in the CKD patient population, with cardiovascular disease (CVD) as the leading mortality cause at all stages of CKD. Elevated FGF23 in CKD has been associated with increased odds for all-cause mortality; however, whether FGF23 is associated with positive adaptation in CKD is unknown. To test the role of FGF23 in CKD phenotypes, a late osteoblast/osteocyte conditional flox- Fgf23 mouse ( Fgf23 fl/fl / Dmp1 -Cre +/– ) was placed on an adenine-containing diet to induce CKD. Serum analysis showed casein-fed Cre + mice had significantly higher serum phosphate and blood urea nitrogen (BUN) versus casein diet and Cre – genotype controls. Adenine significantly induced serum intact FGF23 in the Cre – mice over casein-fed mice, whereas Cre + mice on adenine had 90% reduction in serum intact FGF23 and C-terminal FGF23 as well as bone Fgf23 mRNA. Parathyroid hormone was significantly elevated in mice fed adenine diet regardless of genotype, which significantly enhanced midshaft cortical porosity. Echocardiographs of the adenine-fed Cre + hearts revealed profound aortic calcification and cardiac hypertrophy versus diet and genotype controls. Thus, these studies demonstrate that increased bone FGF23, although associated with poor outcomes in CKD, is necessary to protect against the cardio-renal consequences of elevated tissue phosphate.


  • FGF23 Synthesis and Activity

    by Megan L. Noonan, Kenneth E. White

    Purpose of Review The phosphaturic hormone FGF23 is produced primarily in osteoblasts/osteocytes and is known to respond to increases in serum phosphate and 1,25(OH)2 vitamin D (1,25D). Novel regulators of FGF23 were recently identified and may help explain the pathophysiologies of several diseases. This review will focus on recent studies examining the synthesis and actions of FGF23. Recent Findings The synthesis of FGF23 in response to 1,25D is similar to other steroid hormone targets, but the cellular responses to phosphate remain largely unknown. The activity of intracellular processing genes control FGF23 glycosylation and phosphorylation, providing critical functions in determining the serum levels of bioactive FGF23. The actions of FGF23 largely occur through its co-receptor αKlotho (KL) under normal circumstances, but FGF23 has KL-independent activity during situations of high concentrations. Summary Recent work regarding FGF23 synthesis and bioactivity, as well as considerations for diseases of altered phosphate balance, will be reviewed.


  • Open Access

    Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow

    by Erica L. Clinkenbeard, Mark R. Hanudel, Keith R. Stayrook, Hitesh Nidumanda Appaiah, Emily G. Farrow, Taryn A. Cass, Lelia J. Summers, Colin S. Ip, Julia M. Hum, Joseph C. Thomas, et al.

    Early stages of chronic kidney disease (CKD) are characterized by development of progressive anemia[1][1] as well as concurrent marked elevation of the phosphaturic hormone fibroblast growth factor 23 (FGF23).[2][2] As kidney function declines, FGF23 further increases and anemia worsens, due to


  • Novel functions of circulating Klotho

    by Julia M. Hum, Linda O'BRyan, Rosamund C. Smith, Kenneth E. White


  • Open Access

    The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression

    by Julia M. Hum, Erica L. Clinkenbeard, Colin Ip, Taryn A. Cass, Matt Allen, Kenneth E. White


  • Open Access

    Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho

    by Julia M. Hum, Linda M. O’bRyan, Arun K. Tatiparthi, Taryn A. Cass, Erica L. Clinkenbeard, Martin S. Cramer, Manoj Bhaskaran, Robert L. Johnson, Jonathan M. Wilson, Rosamund C. Smith, et al.

    αKlotho (αKL) regulates mineral metabolism, and diseases associated with αKL deficiency are characterized by hyperphosphatemia and vascular calcification (VC). αKL is expressed as a membrane-bound protein (mKL) and recognized as the coreceptor for fibroblast growth factor-23 (FGF23) and a circulating soluble form (cKL) created by endoproteolytic cleavage of mKL. The functions of cKL with regard to phosphate metabolism are unclear. We tested the ability of cKL to regulate pathways and phenotypes associated with hyperphosphatemia in a mouse model of CKD-mineral bone disorder and αKL-null mice. Stable delivery of adeno-associated virus (AAV) expressing cKL to diabetic endothelial nitric oxide synthase–deficient mice or αKL-null mice reduced serum phosphate levels. Acute injection of recombinant cKL downregulated the renal sodium-phosphate cotransporter Npt2a in αKL-null mice supporting direct actions of cKL in the absence of mKL. αKL-null mice with sustained AAV-cKL expression had a 74%–78% reduction in aorta mineral content and a 72%–77% reduction in mineral volume compared with control-treated counterparts (PαKL. Furthermore, cKL stimulated Fgf23 in an FGFR1-dependent manner in bone cells. Collectively, these findings indicate that cKL has mKL-independent activity and suggest the potential for enhancing cKL activity in diseases of hyperphosphatemia with associated VC.


  • Systemic Control of Bone Homeostasis by FGF23 Signaling

    by Erica L. Clinkenbeard, Kenneth E. White

    The regulation of phosphate metabolism as an influence on bone homeostasis is profound. Recent advances in understanding the systemic control of fibroblast growth factor-23 (FGF23) has uncovered novel effectors of endocrine feedback loops for calcium, phosphate, and vitamin D balance that interact with ‘traditional’ feedback loops for mineral metabolism. Not only are these findings reshaping research studying phosphate handling and skeletal interactions, but they have also provided new therapeutic interventions. Emerging data support that the control of FGF23 production in bone and its circulating concentrations is a multilayered process, with some influences affecting FGF23 transcription and some posttranslational modification of the secreted, bioactive protein. Additionally, the actions of FGF23 on its target tissues via its coreceptor α-Klotho, are subject to regulatory events just coming to light. The recent findings of systemic influences on circulating FGF23 and the downstream manifestations on bone homeostasis will be reviewed herein.